- Home
- OCEAW vs TMHC Comparison
OCEAW vs TMHC Comparison
Compare OCEAW & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- TMHC
- Stock Information
- Founded
- OCEAW N/A
- TMHC 1936
- Country
- OCEAW United States
- TMHC United States
- Employees
- OCEAW 7
- TMHC N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- TMHC Homebuilding
- Sector
- OCEAW Health Care
- TMHC Consumer Discretionary
- Exchange
- OCEAW Nasdaq
- TMHC Nasdaq
- Market Cap
- OCEAW N/A
- TMHC N/A
- IPO Year
- OCEAW 2021
- TMHC 2013
- Fundamental
- Price
- OCEAW $0.02
- TMHC $56.44
- Analyst Decision
- OCEAW
- TMHC Buy
- Analyst Count
- OCEAW 0
- TMHC 8
- Target Price
- OCEAW N/A
- TMHC $76.57
- AVG Volume (30 Days)
- OCEAW N/A
- TMHC 1.0M
- Earning Date
- OCEAW N/A
- TMHC 04-23-2025
- Dividend Yield
- OCEAW N/A
- TMHC N/A
- EPS Growth
- OCEAW N/A
- TMHC 18.48
- EPS
- OCEAW N/A
- TMHC 8.27
- Revenue
- OCEAW N/A
- TMHC $8,168,136,000.00
- Revenue This Year
- OCEAW N/A
- TMHC $3.60
- Revenue Next Year
- OCEAW N/A
- TMHC $5.18
- P/E Ratio
- OCEAW N/A
- TMHC $6.82
- Revenue Growth
- OCEAW N/A
- TMHC 10.12
- 52 Week Low
- OCEAW N/A
- TMHC $51.90
- 52 Week High
- OCEAW N/A
- TMHC $75.49
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- TMHC 44.47
- Support Level
- OCEAW N/A
- TMHC $54.26
- Resistance Level
- OCEAW N/A
- TMHC $56.69
- Average True Range (ATR)
- OCEAW 0.00
- TMHC 2.92
- MACD
- OCEAW 0.00
- TMHC -0.17
- Stochastic Oscillator
- OCEAW 0.00
- TMHC 47.44
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.